Search by Drug Name or NDC
NDC 68180-0288-06 Abacavir and Lamivudine 600; 300 mg/1; mg/1 Details
Abacavir and Lamivudine 600; 300 mg/1; mg/1
Abacavir and Lamivudine is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Lupin Pharmaceuticals, Inc.. The primary component is ABACAVIR SULFATE; LAMIVUDINE.
MedlinePlus Drug Summary
Abacavir is used along with other medications to treat human immunodeficiency virus (HIV) infection. Abacavir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. Although abacavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 68180-0288-06Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Abacavir
Lamivudine (Epivir) is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 3 months of age and older. Lamivudine (Epivir-HBV) is used to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and hepatitis B in the blood. Although lamivudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV or hepatitis B virus to other people.
Related Packages: 68180-0288-06Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Lamivudine
Product Information
| NDC | 68180-0288 |
|---|---|
| Product ID | 68180-288_61b0304c-2258-40ed-9fc8-bc363b0906f6 |
| Associated GPIs | 12109902200340 |
| GCN Sequence Number | 057896 |
| GCN Sequence Number Description | abacavir sulfate/lamivudine TABLET 600-300 MG ORAL |
| HIC3 | W5L |
| HIC3 Description | ANTIVIRALS, HIV-SPEC., NUCLEOSIDE ANALOG, RTI COMB |
| GCN | 23167 |
| HICL Sequence Number | 026524 |
| HICL Sequence Number Description | ABACAVIR SULFATE/LAMIVUDINE |
| Brand/Generic | Generic |
| Proprietary Name | Abacavir and Lamivudine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Abacavir and Lamivudine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 600; 300 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | ABACAVIR SULFATE; LAMIVUDINE |
| Labeler Name | Lupin Pharmaceuticals, Inc. |
| Pharmaceutical Class | Cytochrome P450 1A1 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse T |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA204990 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 68180-0288-06 (68180028806)
| NDC Package Code | 68180-288-06 |
|---|---|
| Billing NDC | 68180028806 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (68180-288-06) |
| Marketing Start Date | 2017-03-28 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 1.20913 |
| Pricing Unit | EA |
| Effective Date | 2023-11-22 |
| NDC Description | ABACAVIR-LAMIVUDINE 600-300 MG |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |